Free Answering Brief in Opposition - District Court of Delaware - Delaware

Case 1:06-cv—OOOO2-G|\/IS Document 11-10 Filed O2/14/2006 Page 1 014
_ 1

NCas§1 :06-c\50000d2-GIVIS Document 11-10 Filed 02/14/2006 Page 2pfi4
ows clcaso - lOIl'l€ age 0 3
;Vv
,...,1;,., 1
..... ·1 ``’’‘ i
1 iev iég 1· Eigh .11_ 11
ii 2 ’·=·VV‘ " *. ·
1‘~· zei. 1
1 11 1‘1;“1
; » 1 1 #¤*a·»*1 i tx 4
’‘’'‘
fzx
Liv gw K éyig/$0/ W?/&4v@ W¢=1< c~:f ~1vG‘e>.mA2:.5.%*1:f:¢.z:.§ ®.;.2:¢.:.z¢ z:g>%vl:;:.:.¢¢;2$i§.ilrfgmzxaé gimpq g g V _{,%Q-la: V ` Y a ? H [A 5 MMW ; ;~e:.¢», »» m.»,»¤,<,:.<.m&:,¢>4< esti: Me.:
.,i,»N\»»».»XsW.».\v»»»Wmexe»»“k~,n<,»12eo1~ia»·ax»s~»e¢»ww>>//»<~¤»_;< V il -P-: '-M V
ki} U ; .`rE News Release i 1 *72%*
11,V ,;·HvE5T¤RjHOME·;`”¤lift`? 1111 g
2 1 Y E
1‘°‘ Q gg `1,1, T 11»‘ ,1, if §1i1f11LQZ1_L”'] Qf,1/i E. View printer-friendly version
M c¤iz¤oiz1srri%?>f1?i%1¢?1&§1§¥i:eliiavs
, 1 ‘ ¤ ~ 1‘1.’ ’·’1 i 1 << Batik
.1¥`f1?;%0Y€RVI1EW ‘“ f# 1
[$1}.% 1= ·’ 1 ’’11 1 , ‘ Diomed Receives Notice of Allowance for Key U.S. EVLT Patent
111i 111111; .111111·1i11.1i 311; .11..11.11 1 1111 11 1 ;
>§1 1 xi ANDOVER, Mass., Jul 26, 2005 (BUSINESS wma) -- piomea, ma.,
2 °i11 i”i‘' ‘?]E*¢?.i°%1{E1¥fij,{1°Pi2}‘fYPfQi?Y '11* ilj'11'; a subsidiary of Diomed Holdings, Inc. (AMEX: DIO), a leading
. 11/... , . .—,1 Q
f 11/A i *n’’ r ‘`*_` _ j ‘V‘·*1 developer and marketer of minimally invasive medical technologies, §
INVESTOR FAQ$ig*'f V1 today announced that it has received a Notice of Allowance from l
`1 11 ” ° ‘ the U15, Patent and Trademark Office allowing a patent I
g NEWS encompassing a proprietary marked introducer sheath for use with E
11 its patented EVLT(R) laser treatment for varicose veins. l
1,1.11,. . A,,, A.11.11 1 R
1”11” ;1 ,’'” — [”__‘ The new patent, which includes both product and method claims,
ilfjiQ11Ii1’ ’li1`i.1 ff". ',.l1 1 1 jjj Q 1 1 covers use of an introducer sheath that has graduated markings to E
.1.. V 11. t1 V 6 · . I · · I ·
A aid a physician in moving the laser fiber through the vein at a
‘ { iQ i1ll A °,_i 1.1ri I 1.1lll if desired rate during the procedure. Diomed introduced this technical
M T in`lTYli?j1'i;1`12"i'fi 1'”1,'1l»l TY `'ll 1* innovation to the market in the fourth quarter of 2003. Currently,
», Vi all EVLT(R) procedure kits sold by Diomed contain the marked i
i.·_ , T ’ 111» introducer sheath covered by the patent. Q
1 I "This Notice of Allowance is a significant accomplishment for
1l1i1111il Q ,,11 Dl0med," Stated James A. Wylie, President and Chief Executive
Officer of Diomed Holdings, Inc. "Complementing our pioneering
1_j1A,11ggyERNANcE’1y1 U15. Patent No. 6,389,777, which covers intraluminal laser vein
°V"L??i¥€‘?2’Y1*??€2?Y`l?1i£'”1i£1 1111 11F » treatment procedures, the new patent will provide Diomed with yet
, gi —/ ```1 1/1/V1 g/P} VVi1i. another competitive tool by further strengthening our existing l
»~»; EMAIL ALERTSM ’’'» ’ ’'1°1ii 1 . .. r
111; 1-,i; r11’, 2 { , patent portfolio. §
V i1i1111 1111111 1 11 111·1 11 Q1%1 1V1111 1 1111 1%&%i_ i
, _ _ 1 , lili li°i *`"" Diomed is currently pursuing patent suits in federal court in Boston J
S ` "V ’“»“' /1i''' i‘?*>1[? ·—’· TIL/}”€¤YV<¤ 1‘11. Jx°E::. against Vascular Solutions, Inc., An9i0Dyi’léimlCS, Inc., Total V€l|’\
Solutions, LLC, and CoolTouch, Inc. for infringement of Diomed's g
U.S. Patent Number 6,398,777 covering intraluminal laser
treatment of varicose veins. The AngioDynamics and Vascular g
Solutions patent suits are in the discovery stage which is scheduled
to be concluded in September. The other cases are earlier in the
i
file://\\usnycfp0I\jwtreloa$\My%20Files\AngioDynamics\Angio%20v%20Diomc... 02/09/2006

NQ$s§glé(g§éc\fj0O0l0é)(i2-GMS Document 11-10 Filed 02/14/2006 Paggg§j>(i)i¢l3
legal process. VV f
In a separate suit unrelated to the U.S. Patent 6,398,777
infringement lawsuits, Diomed is taking action against Vascular
Solutions and one of its former employees for trade secret
misappropriation related to their introduction and sale of a marked
sheath.
Diomed declined to comment on how the new patent may impact
its litigation strategy to protect its intellectual property including
patents and trade secrets.
About Diomed
Diomed develops and commercializes minimally invasive medical
procedures that use its proprietary laser technologies and
disposable products. Diomed focuses on Endovenous Laser
Treatment (EVLT(R)) for use in varicose vein treatments,
photodynamic therapy (PDT) for use in cancer treatments, and
dental and general surgical applications. The EVLT(R) procedure
and the Company‘s related products were cleared by the United
States FDA in January of 2002. Along with lasers and single-use
procedure kits for EVLT(R), the Company provides its customers
with state of the art physician training and practice development
support. Additional information is available on the Company‘s
website, www.evlt.com. EVLT(R) is a registered trademark of
Diomed, Inc., Andover, MA.
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: Statements in this news release looking
forward in time involve risks and uncertainties, including the risks
associated with trends in the products markets, reliance on third
party distributors in various countries outside the United States,
reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These
statements relate to our future plans, objectives, expectations and
intentions. These statements may be identified by the use of words
such as “may," "will," "should," "potential," "expects,"
"anticipates," "intends," "plans," "believes" and similar expressions.
These statements are based on our current beliefs, expectations
and assumptions and are subject to a number of risks and
uncertainties. Our actual results could differ materially from those
discussed in these statements. Our Annual Report on Form SEC 10-
KSB (the "Annual Report") contains a discussion of certain of the
risks and uncertainties that affect our business. We refer you to the
file://\\usnycfp0l\jwtreloa$\My%20Fi1cs\AngioDynamics\Angio%20v%20Diomc... 02/09/2006

NCé\a§§‘gl€(gg5écxfj9.)QlQéli2-GMS Document 11-10 Filed 02/14/2006 Pagéegg,3<>(i)143
"Risk Factors" on pages 22 through 37 of the Annual Report for a .r 0
discussion of certain risks, including those relating to our business
as a medical device company without a signihcant operating record
and with operating losses, our risks relating to our
commercialization of our current and future products and “
applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct
· any of its forward-looking statements.
SOURCE: Diomed, Inc.
Diomed Holdings, Inc.
Christopher J. Geberth, 877j434—6633 or 978—824—l8l6
investor—relations@d;i.omedinc.com
OR
Investor Relations:
Cameron Associates
Al eaiambo, 212-554-5488
éi].@Cé1Iii€IOfl•3SSOC.COH\
.2 Site Map . ..,, . H .,.,., €;99Y}”iQi¥¥[email protected]?G§,;Dl9*Â¥i@€?·»;.El3¢¢ ·.,... ...e,.. »... 4.;.i >ii.., < i,,. .; iir, ul ..ii ..l ..¤i .,,e,i ..».»», »z»> ..,.». ;»a¤esism<: A
i
i
G Dr ¤~r» _
file://\\usnycip0l\jwtrcloa$\My%20Filcs\AngioDynamics\Angio%20v%20Diomc... 02/09/2006